ARCHIVES

Ceritinib Demonstrates 58% ORR, 7-month PFS in ALK+ NSCLC

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

Six Years into The Drug Shortage, And The Causes Are Still a Mystery

October 14, 2011

House Figures for NCI, NIH Will Be Known This Week; Senate Probably Will Wait Until After Recess

July 31, 1987

IOM Says “Immediate Steps” Needed To Avert “Crisis” In Cancer Centers Program Funding

April 28, 1989

Prostate Ultrasound Markers Concepts Approved by BSC

October 3, 1986

“Evolving Concept” Looks At Appropriate Early Decision Making In Patient Management

September 28, 1984

FDA Approves Imaging Agent For Recurrent Prostate Cancer

September 28, 2012